Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose nearly 3% in the morning, and the FNC Clear Shower Pretreatment Solution was officially granted a Chinese patent

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose nearly 3% in the morning. As of press release, it had risen 2.47% to HK$12.86, with a turnover of HK$164.403 million.

According to news, on September 14, according to Keji Pharmaceutical's official WeChat account, the company's self-developed FNC (traditional cleansing solution+low dose albumin combined paclitaxel) cleansing pre-treatment plan was officially granted a patent by the State Intellectual Property Office of China. ^{So far, following the US, Japan, and South Korea, the FNC Clear Shower Pretreatment Solution has completed the patent layout for major global markets, marking the full development of a closed loop of intellectual property protection for core technologies related to Keilimei® (Scherichiolenol Injection) on a global scale.}

^{This time, the FNC Clear Shower Pretreatment Plan has been granted a patent in China, which means that the company's protection for Kailimei® has been extended from the level of a single product to the level of an overall treatment plan including cleansing pretreatment, raising the R&D and commercialization threshold for similar competitors, and further consolidating the company's leading position in the field of CAR-T for solid tumors.}